Mark Raffeld

7PUBLICATIONS
166CO-AUTHORS
Liquid biopsiesPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 04, 2025
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.

Linda K Zane, Laura M Yee, Ting-Chia Chang

|Apr 07, 2025
Spatial Analysis of Hereditary Diffuse Gastric Cancer Reveals Indolent Phenotype of Signet Ring Cell Precursors.

Amber F Gallanis, Lauren A Gamble, Cihan Oguz

|Nov 15, 2023
Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants.

Shadin Ahmed, Mary Frances Wedekind, Jaydira Del Rivero

|May 25, 2023
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.

Melissa L Abel, Nobuyuki Takahashi, Cody Peer

|Jul 10, 2020
High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma.

Mark Raffeld, Zied Abdullaev, Svetlana D Pack

Pageof 2

Frequent Collaborators

6 joint publications

Liqiang Xi

3 joint publications

Kenneth D Aldape

2 joint publications

Jung Kim

2 joint publications

James V Tricoli